Possibility of paclitaxel as an alternative radiosensitizer to 5-fluorouracil for colon cancer

被引:25
作者
Hiro, Junichiro [1 ]
Inoue, Yasuhiro [1 ]
Toiyama, Yuji [1 ]
Yoshiyama, Shigeyuki [1 ]
Tanaka, Koji [1 ]
Mohri, Yasuhiko [1 ]
Miki, Chikao [1 ]
Kusunoki, Masato [1 ]
机构
[1] Mie Univ, Grad Sch Med, Inst Life Sci, Div Reparat Med,Dept Gastrointestinal & Pediat Su, Tsu, Mie 5148507, Japan
关键词
5-fluorouracil; colon cancer; paclitaxel; radiosensitivity; PHARMACOKINETIC MODULATING CHEMOTHERAPY; DNA-DAMAGE CHECKPOINT; CELL LUNG-CANCER; RADIATION SENSITIZER; CARCINOMA-CELLS; IN-VITRO; ADJUVANT RADIOTHERAPY; RANDOMIZED-TRIAL; ONCOLOGY-GROUP; RECTAL-CANCER;
D O I
10.3892/or_0000095
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate the feasibility of paclitaxel (PTX) radiosensitization for colon cancer, we investigated the cytotoxic and G2/M checkpoint protein (Chk 1, Wee 1, Bub 1. MAD2) effects of 5-fluorouracil (5-FU) or PTX combined with radiation in the human colon cancer cell line LoVo. Cytotoxicity and radiocytotoxicity were evaluated for each drug by the WST-8 colorimetric assay. The IC20 for each drug was determined as a cytotoxic concentration from a survival curve. LoVo cells were exposed to the IC20 of each drug for 24 h and then irradiated. Expressions of the G2/M checkpoint proteins were confirmed by Western blot analysis. Cytotoxicity was induced by 5-FU or PTX alone in a time-and dose-dependent manner. The IC20 of PTX caused higher radiosensitivity than the IC20 of 5-FU (P<0.05). Western blot analysis revealed different expression patterns of the G2/M checkpoint proteins between 5-FU and PTX pretreatments. 5-FU combined with radiation tended to decrease the expressions of all G2/M checkpoint proteins in a time-dependent manner. PTX combined with radiation maintained high expressions of Chk 1 and MAD2 proteins for 24 h post-radiation and, in particular. MAD2 protein was strongly induced by PTX with high-dose radiation. PTX showed higher radio-sensitization than 5-FU for the colon cancer cell line LoVo and may be an alternative radiosensitizer to 5-FU in the clinical setting.
引用
收藏
页码:1029 / 1034
页数:6
相关论文
共 41 条
[1]   Defining risk levels in locally advanced head and neck cancers:: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501) [J].
Bernier, J ;
Cooper, JS ;
Pajak, TF ;
van Glabbeke, M ;
Bourhis, J ;
Forastiere, A ;
Ozsahin, EM ;
Jacobs, JR ;
Jassem, J ;
Ang, KK ;
Lefèbvre, JL .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2005, 27 (10) :843-850
[2]  
BLEIBERG H, 1989, EUR J SURG ONCOL, V15, P535
[3]  
CHOY H, 1993, CANCER, V71, P3774, DOI 10.1002/1097-0142(19930601)71:11<3774::AID-CNCR2820711147>3.0.CO
[4]  
2-0
[5]   Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline [J].
Chu, Q ;
Vincent, M ;
Logan, D ;
Mackay, JA ;
Evans, WK .
LUNG CANCER, 2005, 50 (03) :355-374
[6]   DEPENDENCE OF FLUORODEOXYURIDINE-MEDIATED RADIOSENSITIZATION ON S-PHASE PROGRESSION [J].
DAVIS, MA ;
TANG, HY ;
MAYBAUM, J ;
LAWRENCE, TS .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1995, 67 (05) :509-517
[7]  
Einzig Avi I., 1996, Am J Ther, V3, P750, DOI 10.1097/00045391-199611000-00003
[8]  
Gray R, 2001, LANCET, V358, P1291
[9]   COMBINED CHEMOTHERAPY AND RADIOTHERAPY COMPARED WITH RADIOTHERAPY ALONE IN PATIENTS WITH CANCER OF THE ESOPHAGUS [J].
HERSKOVIC, A ;
MARTZ, K ;
ALSARRAF, M ;
LEICHMAN, L ;
BRINDLE, J ;
VAITKEVICIUS, V ;
COOPER, J ;
BYHARDT, R ;
DAVIS, L ;
EMAMI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (24) :1593-1598
[10]   Activation of MAD 2 checkprotein and persistence of cyclin B1/CDC 2 activity associate with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells [J].
Huang, TS ;
Shu, CH ;
Chao, Y ;
Chen, SN ;
Chen, LL .
APOPTOSIS, 2000, 5 (03) :235-241